Patents by Inventor Brian William Grinnell
Brian William Grinnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8076298Abstract: The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.Type: GrantFiled: December 10, 2007Date of Patent: December 13, 2011Assignees: Eli Lilly and Company, Indiana University Research and Technology CorporationInventors: Brian William Grinnell, Bryan Edward Jones, Bruce A. Molitoris
-
Publication number: 20110207670Abstract: The present invention provides a method for preventing and/or treating a patient with acute kidney injury caused by a variety of conditions. The method comprises administering to the patient soluble thrombomodulin variants that do not bind thrombin. In conjunction with standard of care, soluble thrombomodulin variants that do not bind thrombin will prevent or reduce acute kidney injury and subsequent morbidity and mortality.Type: ApplicationFiled: October 21, 2009Publication date: August 25, 2011Applicant: ELI LILLY AND COMPANYInventors: David Thompson Berg, Brian William Grinnell, Akanksha Gupta
-
Publication number: 20100087368Abstract: The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.Type: ApplicationFiled: December 10, 2007Publication date: April 8, 2010Applicant: ELI LILLY AND COMPANYInventors: Brian William Grinnell, Bryan Edward Jones, Bruce A. Molitoris
-
Patent number: 7638123Abstract: Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.Type: GrantFiled: February 26, 2007Date of Patent: December 29, 2009Assignee: Eli Lilly and CompanyInventors: Angelina Vucic Ciaccia, Lawrence Mark Gelbert, Brian William Grinnell, Bryan Edward Jones, David Eugene Joyce
-
Publication number: 20080255047Abstract: The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin. In conjunction with standard of care, soluble thrombomodulin will reduce tissue injury and subsequent morbidity and mortality.Type: ApplicationFiled: October 12, 2006Publication date: October 16, 2008Inventors: Brian William Grinnell, Thurman Dwight McKinney, Bruce A. Molitoris
-
Patent number: 7204981Abstract: Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.Type: GrantFiled: March 21, 2001Date of Patent: April 17, 2007Assignee: Eli Lilly and CompanyInventors: Angelina Vucic Ciaccia, Lawrence Mark Gelbert, Brian William Grinnell, Bryan Edward Jones, David Eugene Joyce
-
Patent number: 6630138Abstract: Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity, resistance to serpin inactivation, and increased sensitivity to thrombin activation compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.Type: GrantFiled: July 22, 2002Date of Patent: October 7, 2003Assignee: Eli Lilly and CompanyInventors: Bruce Edward Gerlitz, Brian William Grinnell, Bryan Edward Jones
-
Publication number: 20030073632Abstract: Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.Type: ApplicationFiled: September 10, 2002Publication date: April 17, 2003Inventors: Angelina Vucic Ciaccia, Lawrence Mark Gelbert, Brian William Grinnell, Bryan Edward Jones, David Eugene Joyce
-
Publication number: 20030022354Abstract: Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity, resistance to serpin inactivation, and increased sensitivity to thrombin activation compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.Type: ApplicationFiled: July 22, 2002Publication date: January 30, 2003Inventors: Bruce Edward Gerlitz, Brian William Grinnell, Bryan Edward Jones
-
Patent number: 6489296Abstract: A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.Type: GrantFiled: May 10, 2000Date of Patent: December 3, 2002Assignee: Eli Lilly and CompanyInventors: Brian William Grinnell, Daniel Lawrence Hartman, Sau-Chi Betty Yan
-
Patent number: 6268344Abstract: A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.Type: GrantFiled: October 8, 1999Date of Patent: July 31, 2001Assignee: Eli Lilly and CompanyInventors: Brian William Grinnell, Daniel Lawrence Hartman, Sau-Chi Betty Yan
-
Patent number: 6156734Abstract: A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.Type: GrantFiled: October 8, 1999Date of Patent: December 5, 2000Assignee: Eli Lilly and CompanyInventors: Brian William Grinnell, Daniel Lawrence Hartman, Sau-Chi Betty Yan
-
Patent number: 6071514Abstract: The present invention provides a method of treatment for patients with a variety of thrombotic disorders including, but not limited to, stroke, venous thrombosis, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, and thrombosis as a result of peripheral vascular surgery. Said treatment is a combination therapy with human aPC and antiplatelet agents including, but not limited to, aspirin (ASA), clopidogrel, ReoPro.RTM. (abciximab), dipyridamole, ticlopidine and IIb/IIIa receptor antagonists. The synergy will result in the ability to reduce the dosages of the agents used in the combination therapy.Type: GrantFiled: June 3, 1998Date of Patent: June 6, 2000Assignee: Eli Lilly and CompanyInventors: Brian William Grinnell, Joseph Anthony Jakubowski
-
Patent number: 6008199Abstract: A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.Type: GrantFiled: October 16, 1998Date of Patent: December 28, 1999Assignee: Eli Lilly and CompanyInventors: Brian William Grinnell, Daniel Lawrence Hartman, Sau-Chi Betty Yan
-
Patent number: 5980938Abstract: The present invention provides methods of inhibiting PAI-1 using benzopyrans.Type: GrantFiled: June 25, 1997Date of Patent: November 9, 1999Assignee: Eli Lilly and CompanyInventors: David Thompson Berg, George Joseph Cullinan, Brian William Grinnell, Mark Alan Richardson
-
Patent number: 5962698Abstract: Novel benzothiophenes, and intermediates thereof, and the uses and formulations thereof, are provided by the present invention.Type: GrantFiled: June 3, 1998Date of Patent: October 5, 1999Assignee: Eli Lilly and CompanyInventors: David Thompson Berg, George Joseph Cullinan, Brian William Grinnell, Mark Alan Richardson
-
Patent number: 5948795Abstract: Novel benzothiophenes, ##STR1## wherein R.sub.1, R.sub.2, and R.sub.3 are independently --OH, --OCO(C.sub.1 -C.sub.6 alkyl), --O(CO)O(C.sub.1 -C.sub.6 alkyl), --OCO--Ar, where Ar is phenyl or substituted phenyl, or --O(CO)O--phenyl; and R.sub.4 is N-pyrrolidinyl, N-piperidinyl, or N-hexamethyleneimino, and intermediates thereof, and the uses and formulations thereof, are provided by the present invention.Type: GrantFiled: June 25, 1997Date of Patent: September 7, 1999Assignee: Eli Lilly and CompanyInventors: David Thompson Berg, George Joseph Cullinan, Brian William Grinnell, Mark Alan Richardson
-
Patent number: 5792798Abstract: Methods of inhibiting plasminogen activator inhibitor 1 comprising administering to a human in need thereof an effective amount of a compound having the formula I: ##STR1## wherein R.sup.1 and R.sup.2 are, independently, --H, --C.sub.1 -C.sub.4 alkyl, or taken together with the nitrogen to which they are attached form a pyrrolidine, piperidine, or hexamethyleneimino ring;or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: July 15, 1997Date of Patent: August 11, 1998Assignee: Eli Lilly and CompanyInventors: David Thompson Berg, George Joseph Cullinan, Brian William Grinnell, Mark Alan Richardson
-
Patent number: 5780648Abstract: Benzothiophenes, and uses and formulations thereof, are provided by the present invention.Type: GrantFiled: June 25, 1997Date of Patent: July 14, 1998Assignee: Eli Lilly and CompanyInventors: David Thompson Berg, George Joseph Cullinan, Brian William Grinnell, Mark Alan Richardson
-
Patent number: 5731328Abstract: A method of inhibiting plasminogen activator inhibitor 1 comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: September 4, 1996Date of Patent: March 24, 1998Assignee: Eli Lilly and CompanyInventors: David Thompson Berg, Brian William Grinnell, Mark Alan Richardson